Therapeutic efficacy of two tear supplements in the management of dry eye disease in Saudi Arabia: The Twaiq Mountain Eye Study II.

IF 1.2 Q4 OPHTHALMOLOGY

Saudi Journal of Ophthalmology Pub Date : 2024-08-16 eCollection Date: 2025-04-01 DOI:10.4103/sjopt.sjopt_305_23

Saleh AlShammeri, Saleh A AlKhaldi, Reem T AlMutairi, Hamad A AlZamil, Saad M AlJohani, Saeed AlJohani, Sulaiman AlDakhil

{"title":"Therapeutic efficacy of two tear supplements in the management of dry eye disease in Saudi Arabia: The Twaiq Mountain Eye Study II.","authors":"Saleh AlShammeri, Saleh A AlKhaldi, Reem T AlMutairi, Hamad A AlZamil, Saad M AlJohani, Saeed AlJohani, Sulaiman AlDakhil","doi":"10.4103/sjopt.sjopt_305_23","DOIUrl":null,"url":null,"abstract":"Purpose: Comparison of the effectiveness between a lipid-based (Cationorm® [CTN]) and nonlipid-based (Artelac Advanced®, 0.2% sodium hyaluronate [SH]) tear supplements in the management of dry eye disease.Methods: This was a randomized, single-masked study (0.2% SH vs. lipid-based eye drops) in two parallel groups over 4 weeks. n = 44 patients were evaluated. The outcome of the tear supplements on the ocular surface symptoms, tear meniscus height (TMH), noninvasive tear break-up time (NITBUT), lipid layer thickness (LLT), corneal and conjunctival redness, and strip meniscometry tube (SMTube) were measured after 4 weeks, compared to baseline.Results: Compared to the baseline, a lipid-based (CTN) eye drop achieved a significant reduction in symptoms (14.25 ± 12.70 vs. 38.60 ± 23.13 score, n = 22 patients) at 4 weeks; Artelac Advanced®, 0.2% SH and CTN showed an improvement in TMH, but it was statistically significant improved in CTN group in compared to 0.2% SH group. Statistical analysis showed improvement in NITBUT and corneal and conjunctival redness in both treatment groups. At 4 weeks, the LLT had further increased in Artelac Advanced®, 0.2% SH group. Both eye drops did not change the tear production measured by SMTube after 4 weeks.Conclusion: Both lipid-based (CTN) and nonlipid-based Artelac Advanced®, 0.2% SH eye drops effectively improved tear volume, tear film stability, and ocular surface health. In addition, lipid-based CTN significantly decreased dry eye symptoms compared to Artelac Advanced®, 0.2% SH.","PeriodicalId":46810,"journal":{"name":"Saudi Journal of Ophthalmology","volume":"39 2","pages":"206-211"},"PeriodicalIF":1.2000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240270/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjopt.sjopt_305_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Comparison of the effectiveness between a lipid-based (Cationorm^® [CTN]) and nonlipid-based (Artelac Advanced^®, 0.2% sodium hyaluronate [SH]) tear supplements in the management of dry eye disease.

Methods: This was a randomized, single-masked study (0.2% SH vs. lipid-based eye drops) in two parallel groups over 4 weeks. n = 44 patients were evaluated. The outcome of the tear supplements on the ocular surface symptoms, tear meniscus height (TMH), noninvasive tear break-up time (NITBUT), lipid layer thickness (LLT), corneal and conjunctival redness, and strip meniscometry tube (SMTube) were measured after 4 weeks, compared to baseline.

Results: Compared to the baseline, a lipid-based (CTN) eye drop achieved a significant reduction in symptoms (14.25 ± 12.70 vs. 38.60 ± 23.13 score, n = 22 patients) at 4 weeks; Artelac Advanced^®, 0.2% SH and CTN showed an improvement in TMH, but it was statistically significant improved in CTN group in compared to 0.2% SH group. Statistical analysis showed improvement in NITBUT and corneal and conjunctival redness in both treatment groups. At 4 weeks, the LLT had further increased in Artelac Advanced^®, 0.2% SH group. Both eye drops did not change the tear production measured by SMTube after 4 weeks.

Conclusion: Both lipid-based (CTN) and nonlipid-based Artelac Advanced^®, 0.2% SH eye drops effectively improved tear volume, tear film stability, and ocular surface health. In addition, lipid-based CTN significantly decreased dry eye symptoms compared to Artelac Advanced^®, 0.2% SH.

Abstract Image

查看原文本刊更多论文

两种泪液补充剂治疗沙特阿拉伯干眼病的疗效：Twaiq山眼科研究II

目的：比较脂质型（Cationorm®[CTN]）和非脂质型（Artelac Advanced®，0.2%透明质酸钠[SH]）泪液补充剂治疗干眼症的疗效。方法：这是一项随机、单屏蔽研究（0.2% SH vs.基于脂质滴眼液），在两个平行组中进行，为期4周。对44例患者进行评估。与基线比较，4周后测量泪液补充对眼表症状、泪液半月板高度（TMH）、无创泪液破裂时间（NITBUT）、脂质层厚度（LLT）、角膜和结膜红度以及条状半月板测量管（SMTube）的影响。结果：与基线相比，脂质（CTN）滴眼液在4周时显著减轻了症状（14.25±12.70分对38.60±23.13分，n = 22例）；Artelac Advanced®、0.2% SH和CTN均可改善TMH，但CTN组较0.2% SH组改善有统计学意义。统计分析显示，两组患者的NITBUT、角膜和结膜红肿均有改善。4周时，Artelac Advanced®0.2% SH组LLT进一步升高。4周后，两种眼药水均未改变SMTube测量的泪液产量。结论：基于脂质（CTN）和非基于脂质的Artelac Advanced®0.2% SH滴眼液均能有效改善泪液体积、泪膜稳定性和眼表健康。此外，与Artelac Advanced®0.2% SH相比，基于脂质的CTN可显著减轻干眼症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Saudi Journal of Ophthalmology OPHTHALMOLOGY-

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Saudi Journal of Ophthalmology is an English language, peer-reviewed scholarly publication in the area of ophthalmology. Saudi Journal of Ophthalmology publishes original papers, clinical studies, reviews and case reports. Saudi Journal of Ophthalmology is the official publication of the Saudi Ophthalmological Society and is published by King Saud University in collaboration with Elsevier and is edited by an international group of eminent researchers.